The effect of L-dopa on monoamine metabolites in Parkinson's disease.
D006916:5-Hydroxytryptophan / Q000378:metabolism; D000368:Aged; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use*; D004298:Dopamine / Q000378:metabolism; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid*; D008875:Middle Aged; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors; D010300:Parkinson Disease / Q000188:drug therapy / Q000378:metabolism*; D010648:Phenylacetates / Q000134:cerebrospinal fluid*; D012701:Serotonin / Q000096:biosynthesis; D013237:Stereoisomerism; D014443:Tyrosine / Q000097:blood / Q000134:cerebrospinal fluid*
D010648:Phenylacetates; D012701:Serotonin; D014443:Tyrosine; D006897:Hydroxyindoleacetic Acid; D004295:Dihydroxyphenylalanine; D006916:5-Hydroxytryptophan; D006899:Mixed Function Oxygenases; D004298:Dopamine